论文部分内容阅读
支气管哮喘(简称哮喘)是一种慢性气道炎症性疾病，具有明显的异质性和复杂的病理生理表现。我国成人的哮喘患病率为1.24%，其中重症哮喘占5.99%。重症哮喘表现为控制水平差，是哮喘致残、致死的主要原因，临床治疗棘手。近年来，针对辅助T细胞(helper T cell, Th)2和Th17表型的生物靶向治疗药物成为哮喘新药开发的热点之一。生物靶向治疗药物为重症哮喘患者带来了新的希望。现就重症哮喘靶向治疗的研究现状进行综述，以期为临床医师治疗重症哮喘提供参考。“,”Bronchial asthma(asthma) is a chronic airway inflammatory disease with obvious heterogeneity and complex pathophysiological manifestations. The prevalence of asthma in Chinese adults is 1.24%, of which severe asthma accounts for 5.99%. Severe asthma manifests as poor control which is the main cause of disability and death of asthma. Clinical treatment of severe asthma is tricky. In recent years, bio-targeted therapeutics targeting at the helper T cell (Th)2 and Th17 phenotypes have become one of the hot spots in the development of new asthma drugs. Bio-targeted therapeutics may be a new hope to patients with severe asthma. This review summarizes the research status of targeted therapy for severe asthma, hoping to provide reference for clinicians to treat severe asthma.